Data as of 9:50am ET
| +0.02 / +0.24%|
Depomed, Inc. manufactures and distributes pharmaceutical products. It is a specialty pharmaceutical company focused on the development and commercialization products to treat pain and other central nervous system conditions. Its core products include Gralise (gabapentin), a once-daily product for the management of postherpetic neuralgia; Zipsor (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain; and Lazanda (fentanyl) nasal spray, a product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The company has developed and licensed a drug-delivery technology, Acuform. Depomed was founded by John W. Shell on August 7, 1995 and is headquartered in Newark, CA.
|James A. Schoeneck||President, Chief Executive Officer & Director|
|August J. Moretti||CFO, Senior VP & Head-Investor Relations|
|Michael Sweeney||Chief Medical Officer, VP-Research & Development|
|Gerd G. Kochendoerfer||Vice President-Technical Development & Quality|
|Matthew M. Gosling||Senior Vice President & General Counsel|